ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.84
1.09%
US Tech 100
20,621.60
0.84%
S&P 500
5,927.27
0.78%
US Dollar vs CAD
1.44261
0.35%
Bitcoin
97,022.24
2.79%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immuneering Corporation (IMRX)

  7. Immuneering Corporation (IMRX) News

IMRX

Immuneering (IMRX)

Immuneering Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMRX
DateTimeSourceHeadlineSymbolCompany
12/19/20247:00AMGlobeNewswire Inc.Immuneering Launches Pancreatic Cancer Advisory BoardNASDAQ:IMRXImmuneering Corporation
12/17/20247:00AMGlobeNewswire Inc.Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025NASDAQ:IMRXImmuneering Corporation
12/12/20247:00AMGlobeNewswire Inc.Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaNASDAQ:IMRXImmuneering Corporation
11/27/20247:00AMGlobeNewswire Inc.Immuneering to Present at the Piper Sandler 36áµ—Ê° Annual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
11/13/20243:05PMGlobeNewswire Inc.Immuneering Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
11/13/20243:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
10/15/202412:00PMAllPennyStocks.comBiotech Shares Rip Following FDA Designation AnnouncementNASDAQ:IMRXImmuneering Corporation
10/15/20247:00AMGlobeNewswire Inc.Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
10/02/20243:11PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:IMRXImmuneering Corporation
09/17/20243:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
09/13/20248:40AMAllPennyStocks.comBiotech Surges Premarket Following Positive Phase 2a ObservationsNASDAQ:IMRXImmuneering Corporation
09/12/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
09/12/20243:05PMGlobeNewswire Inc.Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer PatientsNASDAQ:IMRXImmuneering Corporation
08/29/20247:00AMGlobeNewswire Inc.Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
08/06/20243:12PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMRXImmuneering Corporation
08/06/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
08/06/20243:05PMGlobeNewswire Inc.Immuneering Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
07/31/20243:05PMGlobeNewswire Inc.Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
06/13/20243:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
06/13/20243:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
05/29/20243:05PMGlobeNewswire Inc.Immuneering to Present at the Jefferies Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
05/23/20243:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20243:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20243:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
05/07/20243:05PMGlobeNewswire Inc.Immuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
05/07/20243:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
05/06/20243:30PMGlobeNewswire Inc.Immuneering Recognizes Melanoma Awareness MonthNASDAQ:IMRXImmuneering Corporation
04/09/202411:00AMGlobeNewswire Inc.IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsNASDAQ:IMRXImmuneering Corporation
 Showing the most relevant articles for your search:NASDAQ:IMRX

Your Recent History

USOTC
CEOS
CeCors (PK)
USOTC
ASII
Accredited Solutions (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
AFFU
Affluence (PK)
NASDAQ
TSLA
Tesla
COIN
XRPUSD
Ripple
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
COOP
Mr Cooper
USOTC
TPTW
TPT Global Tech (CE)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
SPZI
Spooz (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
CGAC
Code Green Apparel (PK)
NASDAQ
AMRN
Amarin
USOTC
RDAR
Raadr (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads